both investigated drugs are well established in the treatment of heart failure or hypertension respectively. As the investigateed Patients have this conditions according to the inclusion criteria, treatment will be given as clinical appropriate. Background thearpy will be given according the guidelines of the ESC over the study period.
Conditions
Interventions
Trade Name: micardis
Pharmaceutical Form:
Trade Name: Blopress
Pharmaceutical Form:
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: · Men and women aged 18 years or older with symptomatic chronic heart failure proven by echocardiography or Tc-Szintigraphy ( EF =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: · systemic cortison treatment · patients who are on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis · patients who suffer from infection or malignant disease · childbearing age or lack of anticonceptive treatment during the study period HBA1c >8.5% on treatment of glitazones
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: In chronic heart failure (CHF) changes in heart function are associated with alterations in peripheral perfusion and glucose metabolism. Whole body insulin resistance is prevalent in CHF patients with either ischemic heart failure or idiopathic dilated cardiomyopathy . Recent in vitro and animal studies strongly suggest that telmisartan, unlike other angiotensin II receptor blockers, acts as a partial peroxisome-activated receptor-gamma (PPARy) agonist. PPARy agonists are used to improve insulin sensitivity and lipid profile in type 2 diabetes. Thus we compare the effect of the investigated substances Telmisartan and Candesartan on insulinsensitivity by a frequently sampled oral glucose tolerance test and a frequently sampled intravenous glucose tolerance test. We hypothezise, that the effect of Telmisartan is more pronounced compared to Candesartan. ;Secondary Objective: As heart failure influence glucosemetabolism, treatment is able to influence glucosemetabolism. Natriuretic peptides are proven to be the best surrogate parameter of the severity of heart failure. Thus we use natriuretic peptides to correlate insulin resistance with the severity of the disease before and after treatment. Up to now, no data are available about this question.;Primary end point(s): Is there a difference in improvement of insulin sensitivity between the two treatment groups Are there correaltion between natriuretic peptides ( as a surrogate for severity of heart failure) and impaired glucosemetabolism. | — |
Countries
Austria
Outcome results
None listed